China-based Contract Development and Manufacturing Organization (CDMO) GenScipt Biotech Corp. (HKG: 1548) has revealed the expansion of its manufacturing facility for oligonucleotide and peptide products at Zhenjiang, Jiangsu province. This strategic move aims to enhance the company’s production capabilities to meet the growing demand for these specialized products.
Enhanced Oligonucleotide Synthesis Capabilities
The expanded facility now offers a range of oligonucleotide synthesis capabilities, including qPCR oligos, NGS oligos, RNA oligos, and DNA oligos. These products are crucial for supporting various applications in molecular diagnostics, RNA interference (RNAi), and genome editing. The expansion underscores GenScipt’s commitment to advancing the field of molecular biology and biotechnology.
Increased Production Capacity for Peptides
In addition to the oligonucleotide capabilities, the facility has added four new dynamic axial compression columns for large-scale peptide production, achieving an average monthly production capacity of more than 5 kg. The expansion also includes 32 square feet of freeze dryers to support the mass freeze-drying process, a critical step in peptide manufacturing. With these enhancements, GenScipt is now able to deliver up to 30,000 peptides per month and offer kilogram-level batch production.-Fineline Info & Tech
